Gabapentin attenuates hyperexcitability in the freeze-lesion model of developmental cortical malformation

Lauren Andresen1, David Hampton2, Amaro Taylor-Weiner3

  • 1Department of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, SC201, Boston, MA, USA; Neuroscience Program, Sackler School of Graduate Biomedical Sciences, Tufts University, 136 Harrison Avenue, SC201, Boston, MA, USA.

Neurobiology of Disease
|August 27, 2014
PubMed

Insights

Gabapentin (GBP) prevents epilepsy by blocking thrombospondin (TSP) and α2δ-1 signaling after neonatal brain injury. This treatment reduces hyperexcitability and seizure activity, offering therapeutic potential for developmental cortical malformations.

Area of Science:

  • Neuroscience
  • Developmental Biology
  • Epileptology

Background:

  • Developmental cortical malformations frequently lead to drug-resistant epilepsy.
  • The precise mechanisms driving epileptogenesis in these conditions remain unclear.
  • Neonatal freeze-lesion (FL) in rodents models these malformations and induces cortical hyperexcitability.

Purpose of the Study:

  • To evaluate gabapentin's efficacy in preventing freeze-lesion-induced epilepsy.
  • To investigate gabapentin's effect on thrombospondin (TSP) and α2δ-1 signaling pathways.
  • To assess gabapentin's potential as an anti-epileptogenic therapy for developmental cortical malformations.

Main Methods:

  • Utilized a neonatal rodent model of cortical malformation (freeze-lesion).
  • Administered gabapentin (GBP) for one week post-lesion to target TSP/α2δ-1 signaling.
  • Assessed in vitro hyperexcitability using glutamate biosensor imaging and field potential recordings.
  • Measured miniature excitatory postsynaptic current (mEPSC) frequency.
  • Evaluated in vivo seizure activity using kainic acid (KA) challenge.

Main Results:

  • Neonatal freeze-lesion induced transient upregulation of TSP and α2δ-1.
  • Gabapentin treatment prevented epileptiform activity in vitro.
  • Gabapentin attenuated freeze-lesion-induced increases in mEPSC frequency.
  • Gabapentin-treated animals exhibited reduced in vivo kainic acid-induced seizure activity.

Conclusions:

  • Early gabapentin treatment following neonatal freeze-lesion can prevent the development of a hyperexcitable cortical network.
  • Blocking TSP/α2δ-1 signaling with gabapentin shows therapeutic promise for minimizing epileptogenesis in developmental cortical malformations.

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K